MDS Makes Three-Year Commitment to the International Union Against Cancer
TORONTO, Feb. 4 /CNW/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading
provider of products and services to the global life sciences markets,
declared its increased commitment to the fight against cancer today
designating it as MDS' major charitable cause. MDS has launched employee
awareness and fundraising events around the world and announced a donation of
nearly $1 million over the next three years to the International Union Against
MDS chose UICC, the world's largest non-governmental association of
cancer-fighting organizations, because of its global mission to fight the
disease. With the support of partners like MDS, UICC acts as a resource for
action and a voice for change through prevention education programs, research
projects, and other initiatives that can make a real difference in saving
lives and improving the quality of life for cancer patients and their families
throughout the world.
"We are thrilled to support the work of the International Union Against
Cancer," said Stephen P. DeFalco, President and Chief Executive Officer of
MDS Inc. "We have great employees at MDS who are committed to this fight both
as a company and as individuals, not only on World Cancer Day but every day
they come to work."
Each year, more than 11 million new cases of cancer are diagnosed and
more than 7 million people die from cancer. Through its life sciences
businesses, MDS wages a fight against cancer every day:
- MDS has identified oncology as a focus area of clinical research
activity and conducts cancer studies around the world as part of its
full set of contract research services.
- MDS partners with pharma and biotech customers using its isotope
technologies to develop new radiotherapeutics to treat cancers like
non-Hodgkin's lymphoma and primary liver cancer.
- MDS produces instruments and reagents researchers use to understand
the disease mechanisms and develop new drug therapies.
MDS is a global life sciences company that provides market-leading
products and services that our customers need for the development of drugs and
the diagnosis and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly
skilled people in 29 countries. Find out more at www.mdsinc.com or by calling
1-888-MDS-7222, 24 hours a day.
Source data: International Union Against Cancer www.uicc.org
For further information:
For further information: Sharon Mathers, Senior Vice-President, Investor
Relations and External Communications, MDS Inc., (416) 675-6777 x34721,